Skip to main content

Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as drugs against tuberculosis (NEW ANTIMYCOBACTERIALS)

Objective

A new drug against tuberculosis (TB) will be developed based on the inhibition of the 1-deoxy-D-xylulose 5-phosphate (DOXP) pathway. The DOXP pathway supplies M. tuberculosis with essential isoprenoids. In mammals, the DOXP pathway is absent and isoprenoids are synthesised by the evaluate pathway. Therefore, inhibitors of the DOXP pathway are non-toxic for the human host. Inhibitors of DOXPreductoisomerase (Dry), key enzymes of the DOXP pathway, are to be developed as potential anti-TB drugs. In addition, the crystal structure of the Gape enzyme will be solved to provide the base for future drug development.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

PHILIPPS UNIVERSITY MARBURG
Address
Marbacher Weg 6
35032 Marburg
Germany

Participants (7)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
France
Address
205,Route De Narbonne 205
31077 Toulouse
FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE
Netherlands
Address
Lange Kleiweg 139
2288 GJ Rijswijk Zh
GENT UNIVERSITY
Belgium
Address
Harelbekestraat 72
9000 Gent
JUSTUS-LIEBIG-UNIVERSITY OF GIESSEN
Germany
Address
58,Sriedrichstr. 24
35392 Giessen
QUEEN MARY AND WESTFIELD COLLEGE - UNIVERSITY OF LONDON
United Kingdom
Address
Mile End Road
E1 4NS London
UNIVERSITE LOUIS PASTEUR, STRASBOURG 1
France
Address
Rue Koeberlé 3
67000 Strasbourg
UNIVERSITE PAUL SABATIER DE TOULOUSE III
France
Address
Route De Narbonne 118
31062 Toulouse